Cognition Therapeutics, Inc. (CGTX)

$2.04

+0.07

(+3.55%)

Market is closed - opens 8 PM, 29 Feb 2024

Insights on Cognition Therapeutics, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 73.4% return, outperforming this stock by 50.3%

Performance

  • $1.90
    $2.06
    $2.04
    downward going graph

    6.86%

    Downside

    Day's Volatility :7.77%

    Upside

    0.97%

    downward going graph
  • $0.90
    $3.49
    $2.04
    downward going graph

    55.88%

    Downside

    52 Weeks Volatility :74.21%

    Upside

    41.55%

    downward going graph

Returns

PeriodCognition Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
91.26%
13.2%
0.0%
6 Months
36.81%
9.7%
0.0%
1 Year
23.12%
15.4%
-6.7%
3 Years
-84.57%
30.3%
-19.6%

Highlights

Market Capitalization
63.3M
Book Value
$0.95
Earnings Per Share (EPS)
-0.79
Wall Street Target Price
6.25
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-60.7%
Return On Equity TTM
-66.9%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-44.7M
Diluted Eps TTM
-0.79
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.95
EPS Estimate Next Year
-1.1
EPS Estimate Current Quarter
-0.24
EPS Estimate Next Quarter
-0.28

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Cognition Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 206.37%

Current $2.04
Target $6.25

Technicals Summary

Sell

Neutral

Buy

Cognition Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc.
-16.17%
36.81%
23.12%
-84.57%
-84.57%
Moderna, Inc.
Moderna, Inc.
-8.24%
-15.49%
-30.7%
-38.88%
325.66%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.93%
19.55%
30.63%
114.52%
130.61%
Novo Nordisk A/s
Novo Nordisk A/s
12.12%
30.39%
73.39%
235.66%
399.41%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.12%
22.56%
48.44%
104.83%
128.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc.
NA
NA
NA
-0.95
-0.67
-0.61
NA
0.95
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.94
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.21
28.21
2.0
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.17
45.17
4.45
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.25
31.25
0.59
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc.
Buy
$63.3M
-84.57%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$35.9B
325.66%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$107.8B
130.61%
28.21
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$544.3B
399.41%
45.17
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$112.0B
128.3%
31.25
36.68%

Institutional Holdings

  • Pathstone Family Office, LLC

    7.13%
  • AIGH Capital Management, LLC

    6.59%
  • Vanguard Group Inc

    2.22%
  • Worth Venture Partners, LLC

    1.65%
  • Carlson Capital LP

    0.94%
  • Perigon Wealth Management, LLC

    0.72%

Corporate Announcements

  • Cognition Therapeutics, Inc. Earnings

    Cognition Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

cognition therapeutics inc. is a drug discovery and development company located in pittsburgh, pennsylvania. founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.

Organization
Cognition Therapeutics, Inc.
Employees
22
CEO
Ms. Lisa Ricciardi
Industry
Services

FAQs